March 16th 2023
The federal agency has taken a vital role in support and implementation of the ongoing PEPFAR initiative.
March 6th 2023
March 2nd 2023
Taking a Daily Oral PrEP or Switching to a Long-Acting Injectable Would Prevent HIV Infections 36% and 44% RespectivelyJanuary 20th 2023
A mathematical modeling study for HPTN 083 demonstrated both forms of PrEP vs not taking anything remained efficacious in preventing infection.
Triumeq PD Positive Opinion Brings Europe Closer to Closing HIV Treatment Gap in ChildrenDecember 16th 2022
Europe’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Triumeq PD, the first dispersible single tablet regimen with dolutegravir, for children living with HIV.
If Priced Right, Long-Acting Injectable Cabotegravir Could Reduce Spread of HIVDecember 13th 2022
For this to be a viable HIV reduction strategy, scale-up demand creation should be coordinated between all partners, the study authors said, and should be fast enough to build momentum and yield the expected results.
Understanding Risks of Developing Multi-Drug Resistant HIVNovember 4th 2022
Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, examine the many factors associated with increased risk of HIV, including substance abuse, unstable housing/food situations, and mental illness.
Prevalence and Challenges Associated With Multi-Drug Resistant HIV InfectionsNovember 4th 2022
Joseph Eron, MD and Daniel R. Kuritzkes, MD, discuss how to define “heavily treatment-experienced” and also discuss the prevalence of various types of drug resistance.